C-MER Medical Holdings Resultados de beneficios anteriores

Pasado controles de criterios 3/6

C-MER Medical Holdings ha aumentado sus beneficios a una tasa media anual de 4.4%, mientras que los beneficios de la industria de Healthcare han experimentado un crecimiento de 6.8% anual. Los ingresos han ido creciendo a una tasa media de 28.8% al año. La rentabilidad financiera de C-MER Medical Holdings es de 4.8%, y sus márgenes netos son de 3.3%.

Información clave

4.4%

Tasa de crecimiento de los beneficios

-0.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	11.3%
Tasa de crecimiento de los ingresos	28.8%
Rentabilidad financiera	4.8%
Margen neto	3.3%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero C-MER Medical Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SZSC:3309 Ingresos, gastos y beneficios (HKD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 24	1,896	63	475
31 Mar 24	1,910	63	489
31 Dec 23	1,924	62	503
30 Sep 23	1,862	28	505
30 Jun 23	1,801	-7	506
31 Mar 23	1,766	-14	489
31 Dec 22	1,732	-22	472
30 Sep 22	1,602	1	445
30 Jun 22	1,473	23	418
31 Mar 22	1,293	22	389
31 Dec 21	1,113	22	361
30 Sep 21	1,036	25	325
30 Jun 21	959	28	289
31 Mar 21	829	11	249
31 Dec 20	700	-6	209
30 Sep 20	636	-10	185
30 Jun 20	573	-13	161
31 Mar 20	575	14	153
31 Dec 19	576	41	145
30 Sep 19	539	53	129
30 Jun 19	502	64	114
31 Mar 19	466	53	103
31 Dec 18	429	43	91
30 Sep 18	396	35	81
30 Jun 18	363	27	71
31 Mar 18	341	31	64
31 Dec 17	311	40	55
30 Sep 17	293	46	48
30 Jun 17	274	52	42
31 Mar 17	267	55	41
31 Dec 16	249	47	38
31 Dec 15	199	38	31
31 Dec 14	156	22	31

Ingresos de calidad: 3309 tiene ganancias de alta calidad.

Margen de beneficios creciente: 3309 pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 3309 han crecido un 4.4% al año en los últimos 5 años.

Acelerando crecimiento: 3309 ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: 3309 ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (7.8%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 3309 (4.3%) se considera baja.

C-MER Medical Holdings Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Recent updates

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 21%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado